Covimro

Covimro is an investigational **food-grade broad-spectrum antiviral small molecule** being developed by **COVIMRO**. Publicly available information indicates preclinical antiviral activity against multiple viral families, including **coronavirus**, **lentivirus HIV**, and **influenza A H3N2**, with reported in vitro and animal-model testing conducted by academic and contract research groups between 2020 and 2021. The precise active ingredient, molecular structure, biological target, route of administration, and clinical formulation have not been publicly disclosed, so its mechanism of action remains undefined from the available evidence. Based on the disclosed data, Covimro appears to be an early-stage preclinical antiviral candidate intended for prevention or treatment of viral infections.